Chugai, a Japanese pharma owned by Roche, is partnering with a small Swiss biotech to work on next-generation antibody-drug conjugates that deliver multiple cytotoxic molecules.
Chugai will pay an undisclosed upfront to Araris Biotech and ...
↧